0001711279-26-000043
SEC filingExceptional Q1 marked by 32% VYJUVEK revenue growth from Europe and Japan expansion, delivering 48% operating income increase to $53.7M at 46.1% margin, fueled by strong cash generation from settlement resolution and earnings power.
Krystal Biotech's product revenue, net rose 31.9% year-over-year to $116.4 million, driven by higher VYJUVEK sales compared to the prior year, primarily due to continued growth in Europe and Japan markets. Successful pricing negotiations completed in Japan prior to launch enabled timely market entry, while sustained European demand highlights VYJUVEK's traction in dystrophic epidermolysis bullosa treatment. Investors should note ongoing pricing discussions in Germany (expected resolution in H2 2026) and France (2027), which could further accelerate topline as additional markets open, though timelines carry execution risk.
Operating income climbed 48.4% to $53.7 million, yielding a 46.1% margin on elevated revenue. This reflects VYJUVEK's gross margin profile—defined as product revenue net less cost of goods sold—as manufacturing scales efficiently, even as cost of goods sold incorporates certain period costs and inventory adjustments. Net income advanced 56.5% to $55.9 million, with diluted EPS up 52.5% to $1.83, demonstrating earnings power from revenue momentum and controlled expense growth despite rising R&D and SG&A tied to global commercialization.
Management expects continued expense growth to support global VYJUVEK efforts, with pricing progress critical. Strong FCF and resolved legal matters enable disciplined execution, though investors should watch negotiation timelines, operating leverage, and expense control as headwinds like B-VEC regulatory fees timing or inventory charges may arise.